AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03882398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance
Description: Balance program (10 minutes)~Balance on bosu ball and ball drills Coordination in rings with single leg stance and ball drills Straight line walk with head up Straight line walk and hip flexion, knee flexion and head up~(Duration: 10 minutes. Sets: 2 minutes per exercise. Rest: 30 seconds between exercises)
Study NCT03882398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance
Description: Balance program (10 minutes)~Balance on bosu ball and ball drills Coordination in rings with single leg stance and ball drills Straight line walk with head up Straight line walk and hip flexion, knee flexion and head up~(Duration: 10 minutes. Sets: 2 minutes per exercise. Rest: 30 seconds between exercises)
Study NCT03882398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance
Description: Progressive-cycle program (15-25 minutes)~Warming up Pedalling with 0 resistance (2 minutes)~Main Part\* Week 1-2 : 3x2 minutes Week 3-4 : 4x2 minutes Week 5-6 : 5x2 minutes Week 7-8 : 6x2 minutes~Return to resting stage Pedalling with 0 resistance (1 minute)~(\*Pedalling with resistance set at 3-4. Rest: 2 minutes between sets or 120 beats/minute. One more set added every two weeks and workout intensity maintained at 70% of heart rate reserve-HRR)
Study NCT01794013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent training
Description: All parents in the intervention group had to learn about DIR/ Floortime™ model approach through one on one coaching (1 hour/ session for three sessions) and through 2 hours DVD lecture.
Study NCT01794013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: routine care
Study NCT02779673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoghurt drink containing plant stanol as esters
Study NCT02779673 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yoghurt drink without plant stanol as esters
Study NCT01123226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal manipulation
Description: A maximum of two high velocity low amplitude spinal manipulations to one dysfunctional spine joint
Study NCT01376726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sub C gp140 Vaccine
Description: Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination.
Study NCT01376726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59C.1 Adjuvant
Description: Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination.
Study NCT01123226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trigger point therapy
Description: The thumb will apply firm pressure to a trigger point in the paravertebral multifidus and rotatores muscles associated with the spine joint dysfunction using the barrier approach. This will be held until the barrier releases and this will continue until the trigger point is inactivated or 3 minutes has passed.
Study NCT04161690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol
Description: intravenous dexketoprofen 50mg or intrathecal
Study NCT04161690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrochloride 7.5 MG/ML
Description: Local Infiltration Analgesia
Study NCT04161690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine Hydrochloride 7.5 MG/ML
Description: Local Infiltration Analgesia
Study NCT01936883 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR
Description: High dose rate brachytherapy
Study NCT03655574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational + Family Check-up (MET+FCU)
Description: In the MET session, motivational strategies of individualized normative feedback, examining decisional balance, and providing information/advice will be used to support goals for behavior change and to examine barriers to changes. There are four specific phases of the FCU session: (1) Self-assessment: Parents are asked if they learned anything about their family from participating in the assessment. (2) Support and clarification: The interviewer supports the parent's self-assessment efforts, assesses their level of understanding, and clarifies issues within the family. (3) Feedback: A summary form of the assessment is reviewed. (4) Action Plan: Throughout the session, the counselor works with the parent to develop a brief, written Action Plan about communication and monitoring.
Study NCT03655574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation about substances is provided to teens and parents.
Study NCT01936883 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LDR
Description: Low dose rate brachytherapy boost
Study NCT04123301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Theta Burst Stimulation (TBS)
Description: Each session will be comprised of ACTIVE TBS: first, continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
Study NCT04375241 — intervention group
Intervention type: OTHER
Intervention: Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
Description: Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
Study NCT01237561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: provider support tools plus spirometer
Description: Patient Activation Tool, Provider Web-based decision support tool, academic detailing
Study NCT04387318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal training
Description: IMT will be performed using the POWERbreathe® Medic Plus inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. The IMT wil be performed two times per week for 8 weeks.~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
Study NCT04387318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT + Pulmonary Rehabilitation
Description: IMT will be performed using the POWERbreathe® Medic Plus (POWERbreathe Medic Plus ®, SP, BR) inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. After that, load increases occurred as follows: 35% of MIP in week 3, 40% of MIP in week 4, 45% of MIP in week 5, 50% of MIP at week 6, 55% of MIP in week 7, and 60% of MIP in weeks 8.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
Study NCT04387318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES + Pulmonary Rehabilitation
Description: NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
Study NCT04387318 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
Study NCT04568031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% (w/v) saline
Description: For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.
Study NCT02527018 — intervention group
Intervention type: DEVICE
Intervention: Sphygmomanometer
Description: Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
Study NCT01884428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration
Study NCT01884428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration
Study NCT01884428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration
Study NCT01884428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration
Study NCT01884428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
Study NCT02575976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive CR
Description: In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
Study NCT02575976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise-based CR
Description: The main program is 6 months in duration, with 36 1-hour exercise sessions.
Study NCT02575976 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: wait list control
Description: No cardiac rehabilitation.
Study NCT02660528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Subcutaneous tocilizumab
Study NCT01892657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer with SPF 50+
Description: All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
Study NCT01124357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovaSure
Description: Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
Study NCT01124357 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: thermachoice
Description: ThermachoiceTM III thermal balloon ablation
Study NCT00031122 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention in this study
Study NCT03221348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHO-H01
Description: Glyco-engineered anti-CD20 antibody
Study NCT03308539 — intervention group
Intervention type: RADIATION
Intervention: echocardiography and cardiac magnetic resonance
Description: transthoracic echocardiography and magnetic resonance imaging of the heart
Study NCT04714229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine
Description: 0.5mL single intramuscular dose on Day 0
Study NCT04714229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine
Description: 0.5mL single intramuscular dose on Day 0
Study NCT02497313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Study NCT02497313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Study NCT02497313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin placebo
Study NCT02497313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin placebo
Study NCT02497313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystokinin
Study NCT02497313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01677923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg BID for 12 months
Study NCT04030182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Level of Vitamin D
Description: 3 ml of venous blood will be taken to determine the level of vitamin D
Study NCT02375919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PERC based Strategy
Description: work up for diagnosis of PE includes calculation of PERC
Study NCT02063243 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intralesional cryotherapy
Description: Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
Study NCT02622113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (TA-7284)
Description: The patients will receive Canagliflozin orally for 36 weeks
Study NCT02622113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Study NCT02592109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Counseling using CFR based on Linear Programming
Study NCT02592109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Counseling using CFR based on Linear Programming
Study NCT02575274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical flaps
Description: Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
Study NCT02575274 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical flaps
Description: Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
Study NCT01242930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat (7.5 mg/kg)
Description: Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
Study NCT01242930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide standard of care
Description: Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
Study NCT01242930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat (9.4 mg/kg)
Description: Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
Study NCT03846713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-thermosoftening
Description: By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into normal saline at room temperature.
Study NCT03846713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thermosoftening
Description: By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into warm normal saline (40°C).
Study NCT02613325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional photoacoustic microscopy
Description: -Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
Study NCT02613325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care surgical excision
Study NCT02613325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single cell photoacoustic microscopy
Study NCT01678001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xeomin
Description: Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
Study NCT01678001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin
Description: Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
Study NCT01689818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: exercise training program which included aerobic exercise for 3 times per week.
Study NCT05050890 — intervention group
Intervention type: OTHER
Intervention: ctDNA level during neoadjuvant chemotherapy
Description: ctDNA samples will be collected from patients at baseline, during neoadjuvant therapy (every 15 days) and before the surgical procedure
Study NCT00891748 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AdCD40L
Description: Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
Study NCT01463436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavone
Description: 100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
Study NCT04123301 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Theta Burst Stimulation (TBS)
Description: The sham-TBS sessions will be performed using an identical coil that produces SHAM Stimulation: first, sham continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by sham intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
Study NCT04182789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN035
Description: KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
Study NCT02965638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: The intervention arm (Oxygen Group) will receive oxygen via nasal cannula at a rate of 4L of FiO2 93-100% from an oxygen concentrator up to 24 hours daily
Study NCT02849626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: E2007
Study NCT05304000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: Participants are informed they should sit down in a chair or, if they preferred, to lie down, and then to set a timer for 5 minutes. Then they are told to close their eyes and to start breathing while focusing their mental attention on their forehead region between their two eyes. They are told that if their focus drifted from that location to re-recenter their attention by focusing back first on their breath and then on the forehead region between their eyes. They are told that as thoughts arise, to recognize that as normal, refocus their attention back to their forehead region and to continue the practice until time has elapsed.
Study NCT05304000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cyclic Sighing Breathing
Description: Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 minutes. Then they are told to inhale slowly, and that once their lungs are expanded, to inhale again once more to maximally fill their lungs -- even if the second inhale was shorter in duration and smaller in volume than the first, and then to slowly and fully exhale all their breath. They are told to repeat this pattern of breathing for 5 minutes. They are also informed that ideally, both inhales would be performed via their nose and the exhale would be performed via their mouth, but that if they preferred, they are welcome to do the breathing entirely through their nose. They are also informed that it is normal for the second inhale to be briefer than the first.